Market Research Future published a Cooked research report on “Global Cell Culture Media Market Research Report – Forecast to 2023” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023.
There are two main types of cell culture media namely natural media and synthetic media. Natural media can be obtained from biological fluids, and synthetic media has additional components such as serum proteins, carbohydrates, cofactors, vitamins, salts. That are added to the natural media. Cell culture media are widely used by number of healthcare organisations such as research institutes, clinical laboratories, and others.
Rise in demand for cell culture media will boost the growth of the cell culture media market across the globe. Furthermore, extensive research and development activities by the biotechnology companies also influence the growth of the market. Standardization and interoperability issues, and high cost of cell culture media and contamination of media restrain the growth of the market.
Get a sample report at https://www.marketresearchfuture.com/sample_request/4462 .
Key players in the market:
Merck (U.S), Corning Incorporated (U.S.), General Electric (U.S.), Thermo Fisher Scientic, Lonza (Switzerland), BD (U.S.), HiMedia Laboratories (India), and others. The key players are engaged in the development of cutting edge technologies to strengthen their position in the market and sustain fierce competition with international as well as local players. Product differentiation is an important factor that is needed to focus by the key players. Geographical expansion is also another strategy for sustaining growth and increase market share.
Key players in Cell Culture Media Market:
Merck develops and markets broad portfolio of 300,000 products across the global. The company is a market leader in pharmaceutical and biotechnological having strong presence in various parts of the world.
- May, 2017: Merck launched “EX-CELL Advanced HD Perfusion Medium. It is off-the-shelf, high-density cell culture media supporting perfusion processes that helps to improve production yield. Increased cost efficiency, reduce risk and enhanced manufacturing flexibility, and increasing access to therapies are major benefits offered by the technology.
- May, 2017: Merck announced the opening of its first joint Process Scale-Up Lab in Bengaluru, India. This lab is a collaboration with Stelis Biopharma. The company focuses on provides end-to-end solutions from process development to scale-up manufacturing for pre-clinical, clinical and commercial supply.
The company manufacturers wide range of products focusing on bone and metabolic health, advanced visualization, anaesthesia delivery, applied intelligence, clinical consumables, computed tomography, contrast media, Diagnostic ECG, EP Recording, GoldSeal – refurbished systems, healthcare IT, and hemodynamic recording.
April, 2017: General Electric FlexFactory manufacturing platform was selected by United BioPharma Inc. (UBP) has selected GE Healthcare’s FlexFactory manufacturing platform focusing on late-stage clinical and commercial production capacity of therapeutic monoclonal antibodies in Hsinchu Industrial Park, Taiwan.
February 2017: The Austrian Centre of Industrial Biotechnology (acib) and General Electric introduced a cell line engineering research collaboration to bring increased productivity to biomanufacturers. The collaboration would focus on identification new tools and methods to modify and optimize the Chinese hamster ovary (CHO) cell line performance.
Browse Complete Report at https://www.marketresearchfuture.com/reports/cell-culture-media-market-4462 .
Thermo Fisher Scientific:
February, 2017: Thermo Fisher Scientific announced the launch of the Gibco StemFlex. Medium.
September, 2017: Thermo Fisher Scientific launched new Gibco B-27 Plus Neuronal Culture System, comprised of B-27 Plus Supplement and Neurobasal Plus Medium.
May, 2017: Thermo Fisher Scientific Release launched Chromogenic Coliform Agar (ISO) for water testing offers easy to read results in samples with low level bacterial contamination.
BD is a medical technology companies delivering products in Biosciences, Cervical cancer screening, Diabetes care, Drug delivery systems, Genomics, Infection prevention,, Infusion, Microbiology solutions, Molecular diagnostics, Software solutions, Specimen collection, Surgical instruments
April, 2017: BD acquired Bard creating a highly differentiated medical technology company focused on delivering innovative healthcare solutions to improve clinical and economic outcomes. This will help BD to maintain leadership position in medication management and infection prevention.
September, 2017: Lonza introduced the CytoSMART 2 System, an updated version of Lonza’s popular CytoSMART System for live cell imaging. The system is featured by an advanced optical system and more powerful camera unit. This system help the researchers to capture higher-resolution images of their cell cultures.
March, 2016: Lonza Launched PowerCHO Advance Media for Improved Protein-Production Yields. It is chemically defined, serum-free media for culturing Chinese Hamster Ovary (CHO) cells. The PowerCHO Advance Media is easy to filter, improved cell-growth promotion and high protein titers. Additionally, it is hydrolysate-free, serum-free and of non-animal origin, the PowerCHO Advance Media were further enhanced to better support high-density CHO cells in suspension. For therapeutic bioprocessing applications, this medium also facilitates both downstream purification and regulatory compliance.
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
P: +1 646 845 9312